Management of Differentiated Thyroid Cancer: The Standard of Care
Anca M. Avram(University of Michigan), Luca Giovanella(University Hospital of Zurich), Helen Nadel(Helios Klinikum Emil von Behring), Katherine Zukotynski(Unknown)
Cited by 59
Related Papers
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419
Pneumatosis Intestinalis and Bowel Perforation Associated With Molecular Targeted Therapy: An Emerging Problem and the Role of Radiologists in Its Management
|American Journal of Roentgenology|2012|109
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma
|Annals of Oncology|2010|105
Contrast Echocardiography Grading Predicts Pulmonary Arteriovenous Malformations on CT
|CHEST Journal|2007|100